Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months
Doctors are hailing “amazing” trial results that show a new drug combination stopped lung cancer advancing for more than 40% longer than the standard treatment.
Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.
About Author
More Stories
Hubris by Johannes Krause and Thomas Trappe review – learning from the Neanderthals
Nasa probe ‘safe’ after closest-ever approach to sun
Plantwatch: the smelly deception of titan arum’s phallic spadix